<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00817336</url>
  </required_header>
  <id_info>
    <org_study_id>08I/C19-0</org_study_id>
    <nct_id>NCT00817336</nct_id>
  </id_info>
  <brief_title>Biomarkers in Schizophrenia</brief_title>
  <official_title>Effect of an NMDA-based Intervention on Biomarker Measures of Cognitive Dysfunction in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathan Kline Institute for Psychiatric Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nathan Kline Institute for Psychiatric Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      N-methyl-D-aspartate (NMDA)-type glutamate receptors are thought to play a pivotal role in
      neurocognitive dysfunction associated with schizophrenia. Further, several novel
      glutamate-based classes of compound are presently in development as potential novel
      treatments for persistent negative and cognitive symptoms. The study will assess
      effectiveness of a NMDA-based intervention on biomarkers related to schizophrenia as a
      mechanism for developing appropriate outcome batteries for future trials of novel compounds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      16 in- or outpatients with DSM-IV-TR schizophrenia or schizoaffective disorder and prominent
      negative symptoms will be recruited for this study. This study will consist of a randomized
      trial of D-serine (60 mg/kg/d) vs. placebo using a crossover design with a 2-week baseline
      lead-in, and two 6-week intervention arms separated by a two week, placebo controlled washout
      period. Biomarkers will be assessed at baseline for each treatment arm, acutely (day 7)
      following treatment initiation, and following 6 weeks of treatment (6 biomarker sessions
      total). Primary biomarker outcome measures will include 1) amplitude of the mismatch
      negativity (MMN) waveform and 2) amplitude of the visual P1 potential. Symptomatic outcome
      measures will include PANSS and composite score of the MATRICS neuropsychological battery.
      The study will be supported from ongoing NIMH-funded Cooperative Drug Development Grant
      (CDDG) to the PI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS Total</measure>
    <time_frame>6 weeks</time_frame>
    <description>Positive and Negative Symptom Scale (PANSS) range 30-210</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MMN Amplitude</measure>
    <time_frame>6 weeks</time_frame>
    <description>Final MMN amplitude</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MATRICS</measure>
    <time_frame>6 weeks</time_frame>
    <description>MATRICS assessing 7 domains (Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning, Visual Learning, Reasoning and Problem Solving, and Social Cognition. Raw scores are converted into a composite T-score (normative mean = 50; standard deviation = 10), where higher values indicated less impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual P1</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>D-serine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D Serine</intervention_name>
    <description>60 mg/kg/day</description>
    <arm_group_label>D-serine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age 18-64

          -  SCID diagnosis of Schizophrenia or Schizoaffective Disorder.

          -  PANSS 3 factor negative symptom (screening and baseline visit 1 and visit 3) score of
             &gt;20 and PANSS total score between 60-110. Any degree of positive symptoms is
             acceptable but the total PANSS score must not exceed 110.

          -  SAS total score less than or equal to 12 and a Calgary Depression Inventory total
             score less than or equal to 10 and suicide (item 8) less than moderate (&lt;2).

          -  Two consecutive CGI ratings at screening and baseline (visit 1 and 3) with no change
             in score.

          -  Estimated Glomerular Filtration Rate (GFR)(a measure of renal function) greater than
             or equal to 60.

        Exclusion criteria:

          -  Organic brain disorder, including epilepsy; mental retardation; or a medical condition
             whose pathology or treatment would likely alter the presentation or treatment of
             schizophrenia or significantly increase the risk associated with any of the proposed
             treatments

          -  Current DSM-IV diagnosis of drug/alcohol abuse in last month and current DSM-IV
             diagnosis of drug/alcohol dependence in last 6 months

          -  Pregnant female patients

          -  Impaired renal function

          -  Significant extrapyramidal symptoms (as reflected by a total score of 10 or above on
             the SAS scale), and depressive symptoms (as reflected by a score of 10 or above on the
             Calgary Depression Scale for Schizophrenia)

          -  Patients who are unable to or unwilling to participate in the Cognitive assessment
             (MATRICS) and the electrophysiology tasks .

          -  Patients on clozapine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel C Javitt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nathan Kline Institute</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>January 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2009</study_first_posted>
  <results_first_submitted>December 15, 2016</results_first_submitted>
  <results_first_submitted_qc>July 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2017</results_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarker</keyword>
  <keyword>EEG</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>NMDA</keyword>
  <keyword>D-serine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>D-serine Followed by Placebo</title>
          <description>subjects received a fixed dose of D-serine 60 mg/kg/day in a randomized, placebo-controlled crossover study of d-serine and placebo each for 6 weeks. Subjects were randomly assigned to receive (d-serine or placebo) in the first treatment phase, followed by two-weeks of single-blind placebo, which was followed by the alternative treatment in a second-phase.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Followed by D-serine</title>
          <description>subjects received a fixed dose of D-serine 60 mg/kg/day in a randomized, placebo-controlled crossover study of d-serine and placebo each for 6 weeks. Subjects were randomly assigned to receive (d-serine or placebo) in the first treatment phase, followed by two-weeks of single-blind placebo, which was followed by the alternative treatment in a second-phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were no statistically significant differences by treatment order</population>
      <group_list>
        <group group_id="B1">
          <title>D-serine Followed by Placebo</title>
          <description>Does not include 1 drop-out during phase 1</description>
        </group>
        <group group_id="B2">
          <title>Placebo Followed by D-serine</title>
          <description>Does not include 1 drop-out during phase 1</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="10"/>
                    <measurement group_id="B2" value="44.6" spread="11"/>
                    <measurement group_id="B3" value="40" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>In-patient number</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chlorpromazine equivalents</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1135" spread="967"/>
                    <measurement group_id="B2" value="795" spread="496"/>
                    <measurement group_id="B3" value="965" spread="760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PANSS total</title>
          <description>Positive and Negative Symptom Scale (PANSS) range from 30-210, with higher scores worse</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.7" spread="9"/>
                    <measurement group_id="B2" value="80.1" spread="10"/>
                    <measurement group_id="B3" value="80.8" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PANSS Total</title>
        <description>Positive and Negative Symptom Scale (PANSS) range 30-210</description>
        <time_frame>6 weeks</time_frame>
        <population>Final score end of six weeks</population>
        <group_list>
          <group group_id="O1">
            <title>D-serine</title>
            <description>60 mg/kg/day
D Serine: 60 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: oral</description>
          </group>
        </group_list>
        <measure>
          <title>PANSS Total</title>
          <description>Positive and Negative Symptom Scale (PANSS) range 30-210</description>
          <population>Final score end of six weeks</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.9" spread="9.3"/>
                    <measurement group_id="O2" value="80" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Cohen's d</param_type>
            <param_value>0.80</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>MMN Amplitude</title>
        <description>Final MMN amplitude</description>
        <time_frame>6 weeks</time_frame>
        <population>Includes 11 subjects with analyzable MMN data</population>
        <group_list>
          <group group_id="O1">
            <title>D-serine</title>
            <description>60 mg/kg/day
D Serine: 60 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: oral</description>
          </group>
        </group_list>
        <measure>
          <title>MMN Amplitude</title>
          <description>Final MMN amplitude</description>
          <population>Includes 11 subjects with analyzable MMN data</population>
          <units>micro volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread=".6"/>
                    <measurement group_id="O2" value="-.21" spread=".9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Cohen's d</param_type>
            <param_value>2.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MATRICS</title>
        <description>MATRICS assessing 7 domains (Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning, Visual Learning, Reasoning and Problem Solving, and Social Cognition. Raw scores are converted into a composite T-score (normative mean = 50; standard deviation = 10), where higher values indicated less impairment.</description>
        <time_frame>6 weeks</time_frame>
        <population>Final score after six weeks</population>
        <group_list>
          <group group_id="O1">
            <title>D-serine</title>
            <description>60 mg/kg/day
D Serine: 60 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: oral</description>
          </group>
        </group_list>
        <measure>
          <title>MATRICS</title>
          <description>MATRICS assessing 7 domains (Speed of Processing, Attention/Vigilance, Working Memory, Verbal Learning, Visual Learning, Reasoning and Problem Solving, and Social Cognition. Raw scores are converted into a composite T-score (normative mean = 50; standard deviation = 10), where higher values indicated less impairment.</description>
          <population>Final score after six weeks</population>
          <units>T score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="7.6"/>
                    <measurement group_id="O2" value="25.7" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.31</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Cohen's d</param_type>
            <param_value>0.41</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual P1</title>
        <time_frame>6 weeks</time_frame>
        <population>includes subjecst with valid visual p1 data</population>
        <group_list>
          <group group_id="O1">
            <title>D-serine</title>
            <description>60 mg/kg/day
D Serine: 60 mg/kg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: oral</description>
          </group>
        </group_list>
        <measure>
          <title>Visual P1</title>
          <population>includes subjecst with valid visual p1 data</population>
          <units>micro volts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.21" spread="1.3"/>
                    <measurement group_id="O2" value="-.54" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.41</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Cohen's d</param_type>
            <param_value>0.41</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>per intervention</desc>
      <group_list>
        <group group_id="E1">
          <title>D-serine/Placebo Crossover</title>
          <description>subjects received a fixed dose of D-serine 60 mg/kg/day in a randomized, placebo-controlled crossover study of d-serine and placebo each for 6 weeks. Subjects were randomly assigned to receive (d-serine or placebo) in the first treatment phase, followed by two-weeks of single-blind placebo, which was followed by the alternative treatment in a second-phase.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joshua Kantrowitz</name_or_title>
      <organization>Nathan Kline Institute</organization>
      <phone>646-774-6738</phone>
      <email>jk3380@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

